Integra LifeSciences (NASDAQ:IART) Updates Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) updated its fourth quarter earnings guidance on Monday. The company provided EPS guidance of $0.81-0.89 for the period, compared to the consensus EPS estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Analyst Upgrades and Downgrades

IART has been the topic of a number of research reports. Truist Financial decreased their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Citigroup lowered their target price on Integra LifeSciences from $20.00 to $16.00 and set a "sell" rating for the company in a research note on Tuesday, October 1st. Bank of America lowered their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Morgan Stanley upped their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a research note on Monday, July 15th. Finally, BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $26.50.

Integra LifeSciences Stock Up 25.1 %

NASDAQ:IART traded up $4.84 on Monday, reaching $24.12. 3,688,497 shares of the stock traded hands, compared to its average volume of 1,098,997. The company's fifty day simple moving average is $18.62 and its 200 day simple moving average is $24.46. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 83.17, a PEG ratio of 0.64 and a beta of 1.08. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.